Vol. 17 No. 1 (2024), NOVEL CORONAVIRUS INFECTION
Vol. 17 No. 1 (2024)
NOVEL CORONAVIRUS INFECTION

Novel Coronavirus Infection COVID-19 in Hairy Cell Leukemia Patients

Published 17.05.2024
Lyubov Vasilevna Plastinina
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
L.S. Al-Radi
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
T.N. Moiseeva
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
I.E. Kostina
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
Yu.A. Chabaeva
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
E.A. Baryakh
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
E.I. Zhelnova
City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
T.A. Tupoleva
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
2024-1
PDF_2024-17-1_50-58 (Russian)

Keywords

hairy cell leukemia
novel coronavirus infection COVID-19
nti-SARS-CoV-2 humoral immune response

How to Cite

1.
Plastinina L.V., Al-Radi L.S., Moiseeva T.N., et al. Novel Coronavirus Infection COVID-19 in Hairy Cell Leukemia Patients. Клиническая онкогематология. 2024;17(1):50-58. doi:10.21320/2500-2139-2024-17-1-50-58
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

Aim. To analyze the characteristics of novel coronavirus infection COVID-19 in hairy cell leukemia (HCL) patients and to assess humoral immune response in those of them who had COVID-19 and/or were vaccinated against SARS-CoV-2.

Materials & Methods. This paper documents the retrospective analysis of the data from 118 HCL patients followed-up at the National Research Center for Hematology from March 2020 to October 2021. Within this period, 99 out of 118 patients had novel coronavirus infection COVID-19; 17 out of 99 COVID-19 patients were vaccinated against SARS-CoV-2 (3 of them prior to being infected and 14 of them after that). The rest of 19 HCL patients without COVID-19 were vaccinated against SARS-CoV-2 during the period from January to October 2021. By the time of HCL diagnosis, the patients were aged 23–74 years (median 47 years), whereas by the time of COVID-19 diagnosis, the age range was 25–82 years (median 55 years). There were 63 men and 36 women.

Results. Severe CT 3–4 lung lesions were diagnosed in 22 (22 %) patients and detected more often (55 %) prior to therapy for advanced-stage HCL. In patients on therapy for advanced-stage HCL and those in remission, the rate of severe lung lesions (CT 3–4) was 17 % in each group. COVID-19 therapy was administered to 49 (49 %) patients in a special hospital. Mortality in the total cohort was 6 % (n = 6) and differed in patients with advanced-stage HCL (n = 4) and those in remission (n = 2). The patients who received anti-CD20 monoclonal antibodies for < 12 months prior to COVID-19 infection, in 42 % (n = 5) of cases showed seronegativity vs. 5 % (n = 1) of patients who received the same therapy > 12 months before COVID-19 was diagnosed.

Conclusion. The most severe COVID-19 was observed in chemotherapy-free patients with advanced-stage HCL compared to patients on therapy or in HCL remission. When anti-CD20 monoclonal antibodies were administered for < 12 months prior to COVID-19 diagnosis, the number of patients with negative anti-SARS-CoV-2-IgG immune response increased 15-fold. Mortality in novel coronavirus infection COVID-19 differed at various HCL stages (in remission and at advanced stage).

PDF_2024-17-1_50-58 (Russian)

References

  1. Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. doi: 10.1186/s13045-021-01177-0.
  2. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–92. doi: 10.1182/blood.2020008824.
  3. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020;6(7):1108–10. doi: 10.1001/jamaoncol.2020.0980.
  4. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. doi: 10.1016/S1470-2045(20)30096-6.
  5. Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106–20. doi: 10.1016/S2213-2600(20)30415-X.
  6. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81. doi: 10.1016/S2213-2600(20)30079-5.
  7. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017. pp. 226.
  8. Cross M, Dearden C. Hairy Cell Leukaemia. Curr Oncol Rep. 2020;22(5):42. doi: 10.1007/s11912-020-00911-0.
  9. Chihara D, Kreitman RJ. Treatment of hairy cell leukemia. Expert Rev Hematol. 2020;13(10):1107–17. doi: 10.1080/17474086.2020.1819231.
  10. Damaj G, Kuhnowski F, Marolleau JP, et al. Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol. 2009;83(3):246–50. doi: 10.1111/j.1600-0609.2009.01259.x.
  11. Bellmann-Weiler R, Burkert F, Schwaiger T, et al. Janus-faced course of COVID-19 infection in patients with hematological malignancies. Eur J Haematol. 2020;105(4):502–4. doi: 10.1111/ejh.13470.
  12. Kohla S, Ibrahim FA, Aldapt MB, et al. A Rare Case of Hairy Cell Leukemia with Unusual Loss of CD123 Associated with COVID-19 at the Time of Presentation. Case Rep Oncol. 2020;13(3):1430–40. doi: 10.1159/000512830.
  13. Lamure S, Salmanton-Garcia J, Robin-Marieton E, et al. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Adv. 2022;6(13):3870–4. doi: 10.1182/bloodadvances.2022007357.
  14. «Временные методические рекомендации “Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)”. Версия 17 (14.12.2022)» (электронный документ). Доступно по: https://normativ.kontur.ru/document?moduleId=1&documentId=438135&ysclid=loin8nb79t343796813. Ссылка активна на 03.11.2023. [«Temporary guidelines “Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)”. Version 17 (14.12.2022)» (Internet). Available from: https://normativ.kontur.ru/document?moduleId=1&documentId=438135&ysclid=loin8nb79t343796813. Accessed 03.11.2023. (In Russ)]
  15. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901. doi: 10.1016/j.annonc.2020.03.296.
  16. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. doi: 10.1016/S1470-2045(20)30096-6.
  17. Yigenoglu TN, Ata N, Altuntas F, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93(2):1099–104. doi: 10.1002/jmv.26404.
  18. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–e745. doi: 10.1016/S2352-3026(20)30251-9.
  19. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):50–2. doi: 10.3109/10428194.2011.570819.
  20. Stewart DJ, Bodey GP. Infections in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer. 1981;47(4):801–5. doi: 10.1002/1097-0142(19810215)47:4<801::aid-cncr2820470428>3.0.co;2-6.
  21. Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma. 1994;13(3–4):307–16. doi: 10.3109/10428199409056295.
  22. Damaj G, Kuhnowski F, Marolleau JP, et al. Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol. 2009;83(3):246–50. doi: 10.1111/j.1600-0609.2009.01259.x.
  23. Dasanu CA, Ichim TE, Alexandrescu DT. Inherent and iatrogenic immune defects in hairy cell leukemia: revisited. Expert Opin Drug Saf. 2010;9(1):55–64. doi: 10.1517/14740330903427951.
  24. Smirnova SY, Al-Radi LS, Moiseeva TN, et al. Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications. Clin Lymphoma Myeloma Leuk. 2021;21(7):427–30. doi: 10.1016/j.clml.2021.02.005.
  25. Shenoi DP, Andritsos LA, Blachly JS, et al. Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. Blood Adv. 2019;3(2):116–8. doi: 10.1182/bloodadvances.2018027466.
  26. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733–40. doi: 10.1111/j.1365-2141.2009.07668.x.
  27. Tiacci E, Park JH, De Carolis L, et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med. 2015;373(18):1733–47. doi: 10.1056/NEJMoa1506583.
  28. Benz R, Siciliano RD, Stussi G, Fehr J. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol. 2009;82(3):194–200. doi: 10.1111/j.1600-0609.2008.01190.x.
  29. Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol. 2020;38(14):1527–38. doi: 10.1200/JCO.19.02250.
  30. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129(5):553–60. doi: 10.1182/blood-2016-01-689422.
  31. Kreitman RJ, Arons E. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. Blood Rev. 2022;51:100888. doi: 10.1016/j.blre.2021.100888.
  32. Liebers N, Speer C, Benning L, et al. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 2022;139(1):142–7. doi: 10.1182/blood.2021013445.
  33. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–73. doi: 10.1182/blood.2021011568.
  34. Lamure S, Dulery R, Di Blasi R, et al. Determinants of outcome in COVID-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. EClinicalMedicine. 2020;27:100549. doi: 10.1016/j.eclinm.2020.100549.
  35. Dulery R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–44. doi: 10.1002/ajh.26209.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2023 Clinical Oncohematology